Strekin AG   Report issue

For profit Phase 3
Founded: Basel Switzerland (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03331627
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Strekin AG

Active Ingredients

Drugs in Phase 3 Trials (1)

pioglitazone (actos) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 3)

Hearing Loss (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1